COVID-19重症肺炎患者における静脈内投与ラブリズマブの有効性および安全性に関する研究

基本情報

NCT ID: NCT04369469
ステータス: 中止
試験のフェーズ: 第3相
試験タイプ: 介入
目標被験者数: 202
治験依頼者名: Alexion Pharmaceuticals, Inc.

概要

This study evaluated the efficacy, safety, pharmacokinetics, and pharmacodynamics of ravulizumab administered in adult participants with coronavirus disease 2019 (COVID-19) severe pneumonia, acute lung injury, or acute respiratory distress syndrome. Participants were randomly assigned to receive ravulizumab in addition to best supportive care (BSC) (2/3 of the participants) or BSC alone (1/3 of the participants). BSC consisted of medical treatment and/or medical interventions per routine hospital practice.

対象疾患

COVID-19 Severe PneumoniaAcute Lung InjuryAcute Respiratory Distress SyndromePneumonia, Viral

介入

Ravulizumab(BIOLOGICAL)

BSC(OTHER)

依頼者（Sponsor）

アレクシオンファーマ合同会社(INDUSTRY)

実施施設 (3)

東京科学大学病院

Bunkyō City, Tokyo-To, Japan

東京医科大学病院

Shinjuku-Ku, Tokyo, Japan

東京慈恵会医科大学附属病院

Minato-Ku, Tokyo, Japan